We are live on
!
Find out more
VP
Vitruvian Partners Portfolio holdings
AUM
$112M
1-Year Est. Return
2.02%
This Fund
S&P 500
This Quarter
Est. Return
-13.99%
1 Year Est. Return
+2.02%
3 Year Est. Return
+35.84%
5 Year Est. Return
+18.92%
10 Year Est. Return
–
AUM
$1.92B
AUM Growth
-$475M
(-20%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-8.32%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
3
Reduced
1
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AYX
Alteryx Inc
AYX
|
+$34.6M |
| 2 |
WKME
WalkMe Ltd. Ordinary Shares
WKME
|
+$23.1M |
| 3 |
API
Agora
API
|
+$12M |
| 4 |
CarGurus
CARG
|
+$10.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marqeta
MQ
|
+$240M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 73.95% |
| 2 | Technology | 17.62% |
| 3 | Industrials | 6.66% |
| 4 | Healthcare | 1.77% |
Similar funds
RTM
JE
GW
SPWM
OCA
APFP
FCU
DM
Vitruvian Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Vitruvian Partners held 8 positions worth $1.92B, down 20% from $2.4B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Vitruvian Partners withdrew a net $160M in Q4 2021, reducing 1 holding. Its largest reduction was Marqeta, cutting an estimated $240M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 74% of assets, up from 66% a quarter earlier, followed by Technology and Industrials.
Against the trend, Vitruvian Partners opened a new position in Alteryx Inc worth $30.4M.
- Vitruvian Partners's largest Q4 2021 buy was Alteryx Inc: 501,721 shares worth $30.4M.
- Vitruvian Partners added most to WalkMe Ltd. Ordinary Shares in Q4 2021, an estimated $23.1M increase.
- Vitruvian Partners's biggest Q4 2021 reduction was Marqeta, cutting an estimated $240M.
- Vitruvian Partners's ten largest holdings make up 100% of its $1.92B portfolio in Q4 2021.
- Vitruvian Partners opened 1 new position and closed 0 in Q4 2021.
- Vitruvian Partners's portfolio value fell 20% quarter-over-quarter to $1.92B.
Based on Vitruvian Partners's 13F filing for Q4 2021, filed 11 Feb 2022.